Reishi Mushroom for Ozempic Face: Akott's Akosky Dance Bets on Adaptogens

In a country where losing 15–20% of body weight in a year has become routine, the cosmetics industry’s most pressing question is not weight loss itself. It is what to do about the hollowed cheeks, sagging jaw, and “Ozempic face” that follow rapid loss of facial fat. At in-cosmetics Global 2026 in Paris (April 14–16), Italian ingredient maker Akott Evolution offered an unexpected answer: a mushroom that traditional Eastern medicine has prescribed for two millennia.

What Akosky Dance is

Akott Evolution introduced Akosky Dance, a new cosmetic active extracted from reishi mushroom (Ganoderma lucidum). It is designed to be paired with another company adaptogen, Akosky Ethernal, to address the simultaneous aging signals seen in GLP-1 users.

“They both have different modes of action that would target the different signs of Ozempic face, like loss of elasticity, wrinkles, fatigue, and stress,” Eylul Eroglu, Akott France’s technical sales representative, told BeautyMatter at the show.

Why adaptogens

GLP-1 drugs (semaglutide, tirzepatide) suppress appetite so powerfully that users can shed 15–20% of body weight in a year. The catch is that fat loss is not selective. Facial fat pads (buccal fat pad, suborbicularis oculi fat) deflate at the same time, leaving the dermal collagen scaffold without the volume it once supported. The skin envelope is unchanged, but the volume underneath has vanished. Reduced protein intake during the dieting phase further slows collagen synthesis.

The cosmetics industry’s standard answers to volume loss have been peptides, retinol, and hyaluronic acid. Akott’s pivot to the adaptogen category is a different bet. Adaptogens, originally a supplement-world term, refer to plants believed to enhance the body’s resistance to stress. Reishi, ginseng, ashwagandha, and rhodiola are the classics.

Reishi in skincare is not new — K-beauty has used fermented reishi extracts since the mid-2010s. What is new is positioning. Akott is not selling “immune boosting” or “radiance.” It is selling a specific symptom cluster tied to one user group.

Three cards reishi holds

Three reishi-derived actives matter most to skin.

First, beta-glucans. In vitro data show stimulation of collagen and elastin production in dermal fibroblasts.

Second, triterpenoids (the ganoderic acid family). These exhibit anti-inflammatory action, hypothesized to suppress NF-κB and slow chronic inflammatory aging.

Third, polysaccharides. They contribute to surface hydration and barrier reinforcement.

These three do not act in isolation. The reason Eastern medicine classified reishi as an “herb for aging well” rests precisely on this multi-target (polypharmacology) pattern. One ingredient touching several pathways is the working definition of an adaptogen.

Pairing with Akosky Ethernal

Akott bundles two ingredients because Ozempic face has multiple causes. Loss of elasticity traces to dermal collagen loss; wrinkles, to disrupted stratum corneum alignment; fatigue, to impaired microcirculation; stress, to cortisol-mediated oxidative damage.

The company has not disclosed which pathway each ingredient owns. Still, the pairing concept itself signals a new pattern in cosmetic formulation. Instead of asking a single active to handle multiple symptoms, two adaptogens are modularly combined to cover several pathways at once.

Industry timing

What makes Akott’s move interesting is the timing. About one in eight American adults has tried a GLP-1 drug. In March 2026, semaglutide patents expired in China and India, opening generic markets. The global user base is poised to multiply over the next two to three years.

Anti-aging cosmetics historically targeted menopausal women in their 50s and 60s. Ozempic face spares no age group. Rapid weight loss carves volume regardless of age, putting 30- and 40-somethings in the same conversation. For the industry, this is effectively a new market category: “post-prejuvenation skin that has already started to sag.”

What this means for Korean consumers

Wegovy (semaglutide) launched in Korea in 2024, and use has expanded quickly. Korea’s MFDS does not publish prescription counts, but industry estimates suggest obesity-clinic prescriptions have more than doubled in H1 2026 versus 2025.

K-beauty has not yet released a product line explicitly labeled for Ozempic face, but adaptogen lines using fermented reishi, ginseng, and rhodiola are already common. Akott’s case shows how an existing ingredient family can be repositioned for a new use scenario. The same reishi extract, when relabeled “facial care during GLP-1 use” instead of “immune boosting,” moves to a different shelf, a different consumer, and a different price point.

A note on missing clinical data

One thing to flag: the materials Akott shared at in-cosmetics 2026 did not include human clinical trial data. In vitro and animal data on adaptogens are abundant, but cosmetic trials structured as “50 GLP-1 users, 6 weeks” do not yet exist for these ingredients.

This is normal at the launch stage of a new active. It also means marketing should not outpace evidence. The hypothesis that reishi can help Ozempic face is reasonable; demonstrated efficacy is a different milestone. For consumers, treating an adaptogen line as supplementary care is the safer frame. When dermal volume loss is severe, dermal fillers and adequate protein intake (1.2–1.6 g/kg/day during weight loss) deserve priority.